scholarly journals Advances in diagnosis and treatment of malignant pleural mesothelioma

2011 ◽  
pp. 91-102
Author(s):  
Giorgio Vittorio Scagliotti ◽  
Giovanni Selvaggi
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Combination Chemotherapy ◽  
Targeted Therapies ◽  
Molecular Basis ◽  
Diagnostic Procedures ◽  
Diagnostic Techniques ◽  
Pleural Mesothelioma ◽  
Therapeutic Approaches ◽  
Combine Chemotherapy ◽  
Rare Malignancy

Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and presentation of disease. New diagnostic procedures are urgently needed, selecting patients in earlier stages to evaluate therapeutic approaches which combine chemotherapy, surgery and radiotherapy. Combination chemotherapy represents the only resource available for advanced disease.The combination of cisplatin and pemetrexed is the treatment of choice. This review summarizes the latest developments in diagnostic techniques and the available therapeutic options for the management of MPM. Particular attention is given to the molecular basis of biologically targeted therapies to be used in the future.

scholarly journals Methotrexate and gemcitabine combination chemotherapy for the treatment of malignant pleural mesothelioma

2013 ◽  
Vol 1 (4) ◽  
pp. 639-642 ◽  
Author(s):  
KOZO KURIBAYASHI ◽  
SHIGERU MIYATA ◽  
KAZUYA FUKUOKA ◽  
AKI MURAKAMI ◽  
SYUSAI YAMADA ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Combination Chemotherapy ◽  
Pleural Mesothelioma

Combination Chemotherapy With Mitoxantrone, Methotrexate, and Mitomycin (MMM Regimen) in Malignant Pleural Mesothelioma

2001 ◽  
Vol 24 (2) ◽  
pp. 143-147 ◽  
Author(s):  
Carmine Pinto ◽  
Antonella Marino ◽  
Monica Guaraldi ◽  
Barbara Melotti ◽  
Edera Piana ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Combination Chemotherapy ◽  
Pleural Mesothelioma

Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: A review of practice in British Columbia

Lung Cancer ◽  
2009 ◽  
Vol 64 (3) ◽  
pp. 308-313 ◽  
Author(s):  
Christopher W. Lee ◽  
Nevin Murray ◽  
Helen Anderson ◽  
Sanjay C. Rao ◽  
Winston Bishop
Keyword(s):  
British Columbia ◽  
Malignant Pleural Mesothelioma ◽  
Combination Chemotherapy ◽  
Pleural Mesothelioma ◽  
First Line

202 Combination chemotherapy with methotrexate, irinotecan, and doxorubicin in malignant pleural mesothelioma: A phase II study

Lung Cancer ◽  
2006 ◽  
Vol 54 ◽  
pp. S49 ◽  
Author(s):  
K. Kuribayashi ◽  
K. Fukuoka ◽  
M. Miyake ◽  
S. Miyata ◽  
T. Nakajima ◽  
...  
Keyword(s):  
Phase Ii ◽  
Malignant Pleural Mesothelioma ◽  
Combination Chemotherapy ◽  
Phase Ii Study ◽  
Pleural Mesothelioma

scholarly journals A Case of Diffuse Malignant Pleural Mesothelioma which Responded Remarkably to Cisplatin-based Combination Chemotherapy and Thermoradiotherapy.

Haigan ◽  
1996 ◽  
Vol 36 (3) ◽  
pp. 285-289
Author(s):  
Masanori Nishikawa ◽  
Yutaka Matsumoto ◽  
Hirotada Ikeda ◽  
Takao Okubo ◽  
Yukio Nakatani ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Combination Chemotherapy ◽  
Pleural Mesothelioma ◽  
Diffuse Malignant Pleural Mesothelioma

scholarly journals Local Therapies and Modulation of Tumor Surrounding Stroma in Malignant Pleural Mesothelioma: A Translational Approach

2021 ◽  
Vol 22 (16) ◽  
pp. 9014
Author(s):  
Daniela Lisini ◽  
Sara Lettieri ◽  
Sara Nava ◽  
Giulia Accordino ◽  
Simona Frigerio ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Asbestos Exposure ◽  
Local Drug Delivery ◽  
Pleural Mesothelioma ◽  
Therapeutic Approaches ◽  
Cell Therapies ◽  
Complex Interactions ◽  
Biologic Effects ◽  
Drug Doses ◽  
Lower Drug

Malignant Pleural Mesothelioma (MPM) is a rare and aggressive neoplasm of the pleural mesothelium, mainly associated with asbestos exposure and still lacking effective therapies. Modern targeted biological strategies that have revolutionized the therapy of other solid tumors have not had success so far in the MPM. Combination immunotherapy might achieve better results over chemotherapy alone, but there is still a need for more effective therapeutic approaches. Based on the peculiar disease features of MPM, several strategies for local therapeutic delivery have been developed over the past years. The common rationale of these approaches is: (i) to reduce the risk of drug inactivation before reaching the target tumor cells; (ii) to increase the concentration of active drugs in the tumor micro-environment and their bioavailability; (iii) to reduce toxic effects on normal, non-transformed cells, because of much lower drug doses than those used for systemic chemotherapy. The complex interactions between drugs and the local immune-inflammatory micro-environment modulate the subsequent clinical response. In this perspective, the main interest is currently addressed to the development of local drug delivery platforms, both cell therapy and engineered nanotools. We here propose a review aimed at deep investigation of the biologic effects of the current local therapies for MPM, including cell therapies, and the mechanisms of interaction with the tumor micro-environment.

Sign in / Sign up

Export Citation Format

Share Document